Diligence memo · auto-generated · as of July 3, 2026

Foundation Medicine, Inc.

Foundation Medicine, Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Foundation Medicine, Inc. operates in Biotechnology, based in CAMBRIDGE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Foundation Medicine, Inc. has raised $115M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).

Largest single filing: $56M on 2012-09-10.

Most recent recorded round closed around 2012-09-10.

Valuation (modeled)modeled

Provath models Foundation Medicine, Inc. at approximately $2.3B (range $173M–$6.0B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.15× the median modeled value of Series C Biotechnology companies in 2010–2012 (19 peers) — value vs value, same stage and era. Within the normal band (115% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 10 months.

Last raise 13.8 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 1.3× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 92% of Biotechnology peers (4293 compared).

Modeled value ranks above 95% of those peers.

Closest niche peers: Insmed Inc, Infinity Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Relypsa Inc, Knopp Neurosciences Inc..

Peoplefiled

18 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.